Table 2.
5–15kHz | |||
---|---|---|---|
F time (4,112) = 5.267 | p = 0.0006 | ||
Bonferroni Post-test | Pre vs. 2 Mon | Pre vs. 3 Mon | Pre vs. 4 Mon |
E | ns | ns | ns |
E+P | ns | ns | t=2.872, p< 0.05 |
Placebo | ns | ns | ns |
Male | ns | t=2.836, p< 0.05 | t=2.562, p< 0.05 |
15–30kHz | |||
---|---|---|---|
F time (4,112) =14.81 | p < 0.0001 | ||
Bonferroni Post-test | Pre vs. 2 Mon | Pre vs. 3 Mon | Pre vs. 4 Mon |
E | ns | ns | ns |
E+P | t=3.104, p<0.01 | t=5.057, p<0.001 | t=6.496, p<0.001 |
Placebo | ns | ns | t=2.717, p<0.005 |
Male | ns | t=2.759, p<0.05 | ns |
| |||
Bonferroni Post-test | 1 Mon vs. 3 Mon | 1 Mon vs. 4 Mon | 2 Mon vs. 4 Mon |
| |||
E | ns | ns | ns |
E+P | t=3.930, p<0.001 | t=5.369, p<0.001 | t=3.392, p<0.01 |
Placebo | ns | ns | ns |
Male | ns | ns | ns |
30–45kHz | |||
---|---|---|---|
F time (4,112) =4.687 | p = 0.0016 | ||
Bonferroni Post-test | Pre vs. 2Mon | Pre vs. 3 Mon | Pre vs. 4 Mon |
E | ns | ns | ns |
E+P | t=3.862, p<0.001 | t=5.088, p<0.001 | t=6.408, p<0.001 |
Placebo | ns | ns | ns |
Male | ns | ns | ns |
| |||
Bonferroni Post-test | 1 Mon vs. 2 Mon | 1 Mon vs. 3 Mon | 1 Mon vs. 4 Mon |
| |||
E | ns | ns | ns |
E+P | t=3.494, p<0.01 | t=4.720, p<0.001 | t=6.039, p<0.001 |
Placebo | ns | ns | ns |
Male | ns | ns | ns |
| |||
Bonferroni Post-test | 2 Mon vs. 4 Mon | ||
|
|||
E | ns | ||
E+P | t=2.545, p<0.05 | ||
Placebo | ns | ||
Male | ns |
ANOVA: Analysis of variance, Pre: Pretreatment, Mon: Post-treatment month, ns: Not significant